Since the first description of thymic carcinoid as a specific entity in 1972 by Rosai and Higa, approximately 92 cases of adrenocorticotropic hormone (ACTH)-producing thymic neuroendocrine associated with Cushing's syndrome (CS) have been described between 1980 and 2011. We report here three new cases of neuroendocrine tumor (NET) of thymus associated with ectopic production of ACTH along with review of recent literature.
INTRODUCTION
Since the first description of thymic carcinoid as a specific entity by Rosai and Higa, 1 approximately 92 cases of ACTH-producing thymic neuroendocrine associated with CS have been described between 1980 and 2011. As thymic carcinoids have a significant degree of cellular atypical and a relatively poor prognosis, they have been reclassified as thymic neuroendocrine carcinomas 2 to distinguish them from pulmonary, pancreatic, and stomach carcinoids, which tend to be less aggressive. We report here three new cases of NET of thymus associated with ectopic production of ACTH along with the review of recent literature.
CASE REPORTS Case 1
A 40-year-old lady presented with generalized body swelling along with weight gain of 16 kg in last 1 year. She had amenorrhea and darkening of skin for past 1 year. She also complained of fatigability, difficulty in climbing stairs, and getting up from squatting position for the past 6 months. She was also detected to be having diabetes mellitus and hypertension for the past 4 months. There was no h/o headache or visual disturbances. Family history was not contributory. On examination, the patient was obese, had rounded face with dark pigmentation. Skin was hyperemic and petechiae were present over the legs. Her blood pressure was 146/94 mm Hg and rest of the general examination was normal. Striae were present over the lower part of the abdomen. She had grade IV muscle power in lower limbs.
Investigations revealed anemia, but all other hematological and biochemical parameters were normal. Basal serum cortisol was 916 nmol/L (n: 110-520). The ACTH level was 143 pg/mL. Overnight dexamethasone suppression test (ONDST) revealed unsuppressible cortisol level of 793 nmol/L. High dose dexamethasone suppression test was nonsuppressible as well. Ultrasonography abdomen did not reveal any adrenal tumor; however, computed tomography (CT) thorax revealed an anterior mediastinal mass (Fig. 1) . Magnetic resonance imaging (MRI) pituitary was normal. Inferior petrosal sinus sampling (IPSS) done was not suggestive of a pituitary source. Hence, a diagnosis of thymic carcinoid as an ectopic source of ACTH secretion was made.
Thymic mass was removed trans-sternally. The tumor was present in the right limb and body of thymus with brachiocephalic, pleural, and pericardial infiltration (Fig. 2) . Tumor was excised along with portion of brachiocephalic vein with primary repair. Histopathology report showed NET (intermediate grade). The patient is doing well in follow-up without recurrence of symptoms.
Case 2
A 36-year-old gentleman was referred to us with anterior mediastinal mass on CT thorax and with a fine-needle aspiration cytology, suggesting an NET. The patient gave history of generalized weakness, weight gain with episodic history of facial flushing. He was also detected to be having hypertension and diabetes of recent onset. He also had multiple episodes of breathlessness which required admission. On examination, a clinical diagnosis of CS was made. Biochemically, ONDST was found to be nonsuppressible, and ACTH level was 108.1 pg/mL. Hence, a diagnosis of ACTH (ectopic)-dependent CS was made.
Patient underwent trans-sternal excision of mass along with thymectomy. The tumor was present in the body of thymus with infiltration of brachiocephalic vein from which the mass could be dissected off (Fig. 3 ). Postoperative recovery was smooth. Histopathology showed intermediate-grade NET ( Fig. 4 ) with immunohistochemistry positive for synaptophysin, chromogranin, neuronspecific enolase, CD-56, and cytokeratin with Ki-67 index being 12%. The patient is recurrence free for last 3 years.
Case 3
A 40-year-old gentleman presented to our outpatient department with chest pain and exertional dyspnea of 2 months duration. The patient was evaluated at local 6 ) and with that the patient was referred to our department. On detailed history taking, there was h/o weight gain, facial puffiness, edema for 4 months. On examination, there was moon facies, dilated veins over neck, striae over thigh, hyperpigmentation confined to hands, feet, and face, with severe proximal muscle weakness. Hence, a diagnosis of hypercortisolism with anterior mediastinal mass was made. Biochemical investigation showed unsuppressed ONDST and low dose dexamethasone suppression test and raised ACTH. In the pituitary, MRI brain showed a suspicious hypodense lesion; therefore, ultrasound-guided fine needle aspiration was planned for thymic mass, which was suggestive of neuroendocrine neoplasm. Final diagnosis of ectopic ACTH syndrome due to a thymic carcinoid was made. After adequate preoperative preparation and under steroid cover, the patient was taken up for surgery. A median sternotomy was performed and the tumor which was in the region of body of thymus was removed. The weight of specimen was 320 gm. Postoperatively, patient required ventilatory support for 3 days. Though the patient was shifted out of intensive care unit, he expired after 3 days due to cardiorespiratory failure. Once an ectopic ACTH source is confirmed, localization is done by contrast-enhanced CT (CECT) chest with 5 mm slices. Functional imaging in the form of octreotide radiolabeled scan can be done, since these tumors are known to express somatostatin receptors in 80% of cases. In contrast with bronchial carcinoids which usually remain occult, thymic ACTH-producing NET can be easily identified on chest imaging. In the series of Neary et al, 3 a thymic tumor was identified in 9 of 11 cases on initial chest imaging (chest X-ray or CECT chest). Although thymic NETs are rarely part of MEN-1, the possibility of MEN-1 should be considered in all patients with thymic NET, especially in male smokers. 8 Preoperatively, patient may be put on short-term medical therapy like ketoconazole, octreotide, aminoglutethimide, mifepristone. Surgery in the form of total thymectomy is the therapy of choice for these tumors. Since aggressive local resection is required, limited approach should be avoided. Median sternotomy is thus indicated in almost all cases. These tumors can be locally aggressive and aggressive resection may include pericardium and pleura. Pass et al 9 have suggested that surgery should include aggressive mediastinal lymph node dissection. In the series by Neary et al, 3 10 patients underwent thymectomy via sternotomy;
DISCUSSION
2 patients underwent thymectomy via thoracotomy. En bloc resection of pericardium was required in 2 patients and excision of pleura in 1 patient. In our series, all the 3 patients underwent thymectomy via median sternotomy. Carcinoid tumors have been reclassified (World Health Organization) as: Grade I (well differentiated) Grade II (well differentiated) Grade III (poorly differentiated).
Majority of thymic carcinoids are grade II. 10, 11 Immunohistochemistry analysis usually shows positive staining with chromogranin A and synaptophysin. Presence of ACTH staining does not necessarily correlate with presence or absence of CS.
Need for adjuvant radiotherapy or chemotherapy is still not clear. Ruffini et al 12 noted that postoperatively radiation therapy may reduce the risk of relapse but has no effect on long-term survival. These tumors are resistant to standard chemotherapy regimes. In the series by Neary et al, 3 3 patients received fractionated mediastinal radiation therapy, 4 also received adjuvant chemotherapy. The behavior of these tumors appears to correlate with histologic grade, which seems directly proportional to degree of differentiation. Despite total thymectomy or aggressive local resection, these tumors carry a poor prognosis and most patients present with local recurrence or metastasis within 5 years after surgery with overall survival of 10 years. In the meta-analysis done by Neary et al, 3 median time to recurrence of CS in 53 patients was 18 months, with median time to death being 35 months. Thymic NET associated with CS has a poor outcome as compared with those without CS. 13 Control of recurrent CS can be done using ketoconazole, metyrapone, or bilateral adrenalectomy, the latter is preferred to highly toxic mitotane. In the meta-analysis the longest disease-free interval was 8 years.
14 Therefore, all patients of NET associated with CS should have extended clinical follow-up with intensive biochemical testing and imaging.
CONCLUSION
In summary, ACTH-producing NET is a rare cause of CS and requires high suspicion to make an early diagnosis and is a locally aggressive disease which requires aggressive surgical resection. Adjuvant radiotherapy may be beneficial.
